Le Lézard
Classified in: Health
Subjects: MAV, CFG

Media Advisory - Prime Minister's itinerary for Thursday, February 1, 2024


OTTAWA, ON, Feb. 1, 2024 /CNW/ -

Note: All times local

Greater Toronto Area, Ontario

The Prime Minister will meet with a family to discuss affordability and housing.

Note for media:

The Prime Minister will meet with young adults to discuss mental health.

Closed to media

This document is also available at https://pm.gc.ca

SOURCE Prime Minister's Office


These press releases may also interest you

at 05:45
Class Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact The Gross Law Firm
The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. . Shareholders who purchased shares of BLUE...

at 05:44
Pharmacy Automation: Revolutionizing Healthcare with Cutting-Edge Solutions
According to the latest BCC Research study, the demand for Pharmacy Automation: Technologies and Global Markets is growing from $7.8 billion in 2023 to $12.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 10.2% from 2023...

at 05:05
Sun Nuclear Showcases New Quality Management Solutions for Radiation Therapy Teams and Workflows at ESTRO Annual Meeting
Sun Nuclear, a Mirion Medical company, will feature new and enhanced solutions for better Quality Management at the ESTRO Annual Meeting, May 3-6, in Glasgow, Scotland. The Sun Nuclear booth (#930) will highlight demonstrations and insights on the...

at 04:32
Charting the Rise: MRI Technologies Soar with a 6.4% CAGR (2023-2028)
According to the latest BCC...

at 03:05
Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology
In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage...

at 02:22
Hansa Biopharma: increase in number of shares and votes
Hansa Biopharma AB (publ), ("Hansa" or the "Company") (STO: HNSA) today announced that the company's registered share capital and number of shares and votes have increased through the issue of 10,474,740 new ordinary shares on 12 April 2024, whereby...

More news about Health...


News published on and distributed by: